News
IMTX
7.14
+2.00%
0.14
Stifel Initiates Coverage of Immatics N.V. at Buy
NASDAQ · 23h ago
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 1d ago
Immatics Price Target Announced at $15.00/Share by Stifel
Dow Jones · 1d ago
Immatics Initiated at Buy by Stifel
Dow Jones · 1d ago
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Benzinga · 1d ago
Immatics initiated with a Buy at Stifel
TipRanks · 2d ago
Weekly Report: what happened at IMTX last week (1005-1009)?
Weekly Report · 3d ago
Weekly Report: what happened at IMTX last week (0928-1002)?
Weekly Report · 10/05 09:50
Weekly Report: what happened at IMTX last week (0921-0925)?
Weekly Report · 09/28 09:47
Weekly Report: what happened at IMTX last week (0914-0918)?
Weekly Report · 09/21 09:47
Weekly Report: what happened at IMTX last week (0907-0911)?
Weekly Report · 09/14 09:50
Weekly Report: what happened at IMTX last week (0831-0904)?
Weekly Report · 09/07 09:46
13D Filings
Barron‘s · 09/04 22:59
Weekly Report: what happened at IMTX last week (0824-0828)?
Weekly Report · 08/31 09:50
Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs
TipRanks · 08/26 21:47
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Seeking Alpha · 08/25 17:45
Immatics price target lowered to $17 from $18 at Jefferies
TipRanks · 08/25 17:35
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Benzinga · 08/25 14:03
Immatics Announces $150 Million Underwritten Offering; Stock Up
NASDAQ · 08/25 12:24
Immatics launches $150M securities offering
Seeking Alpha · 08/25 11:06
More
Webull provides a variety of real-time IMTX stock news. You can receive the latest news about Immatics N.V through multiple platforms. This information may help you make smarter investment decisions.
About IMTX
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.